Indian pricing body initiates action to check essential meds shortage
This article was originally published in Scrip
Executive Summary
India's apex pricing authority has swung into action to tackle the ''scarcity'' of certain essential medicines including an antimalarial combination and rabies vaccines setting sharp compliance timelines for industry. Pharmaceutical firms, meanwhile, claim the current situation is a result of the government's own lopsided pricing policy.
You may also be interested in...
India Specifies Terms For Ceasing Supplies Of Essential Drugs
India's apex pricing authority has specified the modalities for firms wanting to stop supplies of certain essential drugs in the country. Industry, though, claims that the regulator may have exceeded its remit and underscores how a lopsided pricing policy approach can lead to potential shortages.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet